May 1 2018 Ad_BJMCL is an interesting market in that all of the approved products are also indicated for other disease states, but if you are looking for a sponsor for an MCL program, some prospects are better than others.  PDD is different because it tracks communication events over the past 3 years, providing you with insight into which issues are most important to your clients.

In the case of MCL, 60% of the communication activity for Calquence over the past 3 years has focused on MCL. However, the Phase 2 PHILEMON study published in Lancet Haematology in March showed an ORR of 76% in MCL for the three product combination of Imbruvica, Revlimid, and MabThera.  Additionally, a Phase 1 study of umbralisib presented at ICML demonstrated a 79% ORR and a Phase 2 study of the combination of Levact plus MabThera published in Lancet Oncology had a 91% complete response in MCL patients – good indicators that these three products could be potential prospects for MCL marketing activity in 2019 and beyond.

Subscribe today and let PDD provide you with the wisdom of insight.

Making Sense of Mantel Cell Lymphoma